TP53 and pancreatic adenocarcinoma: The current study was inspired by reports [9,10] of the induction of cytotoxic T lymphocytes directed to a synthetic p53-derived peptide (p161 corresponding to residues 161–169 of p53, sequence AIYKQSQHM) in PBMC derived from hepatocellular carcinoma and pancreatic adenocarcinoma A24-carrying patients.